EyePoint Pharmaceuticals Reports Positive Interim Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD

By In The News
November 13, 2021 in The Headlines

Followers 0

Reply to this topic

Recommended Posts

In The News

Posted November 13, 2021

- Share

Posted November 13, 2021

WATERTOWN, Mass., Nov. 13, 2021 /PRNewswire/ -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced six-month interim data from the...

View the full article

Quote

Link to comment

Share on other sites

Reply to this topic...

× Pasted as rich text. Paste as plain text instead

Only 75 emoji are allowed.

× Your link has been automatically embedded. Display as a link instead

× Your previous content has been restored. Clear editor

× You cannot paste images directly. Upload or insert images from URL.

Insert image from URL

Followers 0

Go to topic listing

Most Contributions
1. In The News
  201606
2. Jaydee
  13903
3. Kip Powick
  11835
4. deicer
  10843
5. dagger
  9572
Tell a friend
Love The Airline Website? Tell a friend!
- Email
- Share
Forum Statistics
- Total Topics
  
  251.5k
- Total Posts
  
  523.9k

Sign In

EyePoint Pharmaceuticals Reports Positive Interim Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD

Recommended Posts

In The News

Link to comment

Share on other sites

Most Contributions

Tell a friend

Forum Statistics

Browse

Activity

Support